Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Instem Acquires Market Leader d-wise to Further Accelerate Life Science Development

Instem’s Acquisition of Leading Clinical Trial Technology and Consulting Provider d-wise Represents Substantial Advancement of its Mission

Instem, a leading provider of IT solutions and services to the global life sciences market, announced that it has acquired clinical trial technology and consulting leader d-wise, Inc. (d-wise) as part of its mission to enable clients to bring their life enhancing products to market faster. The further consolidation of key application areas will help customers streamline and accelerate their research and development processes, while access to a broader range of data from across the R&D continuum will increase the power of future in silico modelling and prediction solutions.

Recommended AI News: Digital Leader Lynda Clarizio Joins’s Board of Directors

Founded in 2003, d-wise are well respected clinical trial technology domain experts who advise on and build clinical trial analysis and data anonymization solutions, leveraging open-source and cloud technologies. For 19 of the top 20 global pharmaceutical companies, d-wise has made a significant impact in creating operational and clinical data efficiencies that have accelerated clinical trial analysis and regulatory submissions. d-wise supports its global customer community through its U.S. headquarters based in Research Triangle Park, North Carolina, along with an office location in Manchester, United Kingdom.

Instem sees the acquisition of d-wise as an integral part of its transformational growth strategy, extending its ability to further deliver solutions that meet the rapidly expanding needs of life science organizations for faster data-driven decision making, leading to safer, more effective products.

Related Posts
1 of 33,217

“More than a growth-based acquisition, this can truly help transform the industry landscape,” states Phil Reason, CEO at Instem. “Our combined capabilities will help us meet the demand from our clients to create a more connected ecosystem across the life sciences in the global effort to bring life enhancing products to market faster. And, behind all of the technology, is a highly talented, experienced and motivated d-wise team who shares our mission and values. They are widely trusted industry thought leaders and practitioners, committed to delivering an exceptional client experience.”

Recommended AI News: Cyber Resilience Is the Theme of Datto’s Fourth MSP Technology Day

Reason continues, “The d-wise organization is well known for its drive to transform the life sciences through open and flexible access to data. They act as strategic advisors to many of Instem’s existing clients and are one of the leading IT solution engineering and integration partners in the market today. We are extremely excited about future opportunities to leverage wider areas of data and knowledge, backed by leading technologies and services, to maximize client value in ways we and the industry have only dreamed of in the past.”

John Leveille, CEO at d-wise comments, “Our mission has always been to help our clients navigate technology change in pursuit of human health and wellbeing. Today is a watershed moment in our journey, as we take d-wise products and services to the next level and achieve even greater reach and impact. We are excited to be part of Instem, a growing global organization of over 400 professionals with a shared purpose of helping our clients in their life changing missions.”

Leveille continues, “Instem’s reputation is stellar and we share many of the same core values which will enable a solid cultural fit. Being part of a large, publicly traded organization will enable us to more rapidly develop and introduce new innovative products and services. By providing solutions across a wide area of the life science R&D continuum, I’m certain that as part of Instem we will accelerate clinical development timelines and have an even broader impact on human health and wellbeing.”

Recommended AI News: Cryptocurrency Payments Processing Service Automates Compliance Using Sumsub

Comments are closed.